• CD40–STING–TRAF2 Axis in ESCC B Cells

  2026-10-01

  A 2025 study links tertiary lymphoid structures with favorable survival in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4-high B cells as a central immune feature. Its mechanistic experiments indicate that CD40 and STING compete for TRAF2, shaping non-canonical NF-κB signaling and IRF4-mediated B-cell activation.

• Sulfur Supply Delays Soybean Nodule Senescence

  2026-10-01

  The reference study identifies sulfur delivery into the soybean symbiosome as a regulatory checkpoint that preserves glutathione-dependent scavenging of reactive nitrogen species and delays nodule senescence. Its genetic, mineral-transport, and biochemical evidence connects SULTR-mediated sulfur supply with sustained symbiotic nitrogen fixation and suggests measurable targets for future nodule stress research.

• MMAE as a Functional Probe of Tumor Plasticity

  2026-09-30

  Monomethyl auristatin E (MMAE) is more than a cytotoxic payload: it can help researchers separate tumor-cell state from microtubule vulnerability. This article translates NPC plasticity research into a rigorous assay and translational framework for MMAE-based cancer therapy studies.

• PAD4-IN-2 TFA: Targeted NET Assay Workflows

  2026-09-30

  PAD4-IN-2 TFA, also known as Compound 5i TFA, helps researchers separate tumor-directed uptake from neutrophil PAD4 biology. This workflow-focused guide covers uptake, H3cit, NET, migration, immune-profiling, and troubleshooting strategies for cancer research.

• Psora 4: From Channel Block to Immune Insight

  2026-09-29

  Psora 4 is a selective Kv1.3 blocker for connecting membrane potential, calcium entry, and effector-memory T-cell behavior. This article goes beyond routine workflows by showing how KCNE4-dependent channel architecture changes pharmacological interpretation and disease-model translation.

• Cediranib: Measuring Antiangiogenic Response

  2026-09-29

  Cediranib and AZD2171 can reveal how VEGFR blockade changes signaling, growth, and cell death. This assay-focused guide shows how to separate target engagement from cytotoxicity for more rigorous cancer research conclusions.

• ATRX-Deficient Glioma and PDGFR Inhibitor Sensitivity

  2026-09-28

  Pladevall-Morera and colleagues identified ATRX deficiency as a context associated with increased sensitivity to multiple receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. The study also found enhanced toxicity when selected RTK inhibitors were combined with temozolomide, supporting ATRX-stratified interpretation of treatment responses and clinical trials.

• Entinostat (MS-275) Assays: Arrest vs. Cell Death

  2026-09-28

  Entinostat experiments are easier to interpret when reduced cell growth is measured separately from cell killing. This workflow pairs dose and time courses with viability, death, and histone-acetylation readouts to distinguish cytostatic responses from cytotoxic ones.

• Perospirone Workflows for Receptor and Kv Research

  2026-09-27

  Perospirone (SM-9018 free base) supports receptor-focused schizophrenia research and, in a recent vascular-cell study, concentration-dependent inhibition of voltage-gated K⁺ currents. This practical guide connects those applications with assay workflows, starting conditions, and troubleshooting—while distinguishing established findings from suggested experimental choices.

• CPI-613 Workflows for Tumor Metabolism Studies

  2026-09-26

  Use CPI-613 to probe how disrupting mitochondrial carbon metabolism changes tumor-cell energy status and apoptosis—then pair metabolic readouts with orthogonal death assays to avoid overinterpreting a single endpoint. This practical workflow also explains how to examine ferroptosis-related questions without assuming that CPI-613 directly induces ferroptosis.

• Cediranib (AZD2171) for Reliable Cell Assays

  2026-09-25

  This scenario-based guide explains how to use Cediranib (AZD2171), SKU A1882, to investigate VEGFR signaling while distinguishing pathway inhibition from reduced viability or cell death. It covers model selection, DMSO handling, assay interpretation, and practical criteria for comparing supplier options.

• Dual-Action Inhibitors Accelerate p38α Dephosphorylation

  2026-09-25

  A bioRxiv preprint reports that three kinase inhibitors can both inhibit p38α MAP kinase and increase WIP1-mediated removal of its activation-loop phosphate. Structural comparisons connect this effect to an inhibitor-stabilized, phosphatase-accessible conformation, suggesting a way to investigate kinase inhibition beyond active-site occupancy alone.

• Isoprinosine Workflows for Antiviral Research

  2026-09-24

  Use Isoprinosine to test immune-modulating and antiviral hypotheses without confusing them with direct effects on viral egress. A practical workflow pairs dose and timing screens with HSV-1 replication readouts and CLCC1-focused controls, while keeping the evidence boundaries clear.

• DHA Research: Lipid Identity, Assays, and Evidence

  2026-09-24

  Docosahexaenoic Acid (DHA) is widely studied in neural and retinal biology, but its effects cannot be inferred from other fatty acids. This guide connects DHA assay design with a recent arachidonic-acid vaccine study to clarify what the evidence supports—and what it does not.

• Targeted PAD4 Inhibition: From NET Biology to Translation

  2026-09-23

  PAD4-IN-2 TFA, also known as Compound 5i TFA, pairs PAD4 inhibition with meta-phenylboronic acid-mediated tumor targeting. This article examines the PAD4–H3cit–NET pathway, the evidence behind the compound, and practical ways to test target engagement, selectivity, and translational relevance without overstating what preclinical models show.

8482 records 1/566 page Next 12345 下5页 Last page